In 1983, Dilip Shanghvi started Sun Pharmaceutical Industries with five psychiatric medicines and a rented office in Vapi, Gujarat. Four decades later, it is the largest pharmaceutical company in India and the fourth-largest specialty generics company in the world — a trajectory that tells you something about the man and the industry he helped build.
The thing about Dilip Shanghvi is that he never had a eureka moment. He had a method. His father sold generic medicines in Kolkata; Shanghvi learned the business by watching margins, not molecules. When he founded Sun Pharma in 1983, he chose psychiatric drugs — not because he had a passion for neuroscience, but because the therapeutic category was small, the incumbent manufacturers were few, and the barrier to entry was understanding that Indian psychiatrists needed affordable lithium carbonate and carbamazepine. Five products. No laboratory. No borrowed money from banks.
The company’s first decade was a study in compounding: not the chemical kind but the financial kind. Shanghvi reinvested everything. Revenue grew not through breakthroughs but through what he called “doing the boring things well” — regulatory filings, consistent quality, reliable supply. By 1994, Sun went public on the Bombay Stock Exchange. The IPO raised Rs 550 million. The boring things were starting to pay.
What happened next looks, in retrospect, like a masterclass in strategic acquisition — but at the time, each deal carried genuine risk. In 2010, Sun acquired Taro Pharmaceutical, an Israeli-American company four times the size of Sun’s US operation, gaining dermatology manufacturing and FDA-approved facilities in Haifa and Brampton. In 2012 and 2013, DUSA Pharmaceuticals and URL Pharma followed — giving Sun photodynamic therapy and the colchicine franchise.
Then came the bet that defined the decade. In 2015, Sun acquired Ranbaxy Laboratories from Daiichi Sankyo for $3.2 billion, absorbing twenty-three thousand employees, a tangle of US FDA consent decrees, and manufacturing operations spanning the globe. The deal made Sun the world’s fifth-largest generic company overnight. It also nearly broke them. Integrating Ranbaxy’s quality systems took years, not quarters. Shanghvi later called it “the most difficult thing I’ve done.”
But the acquisitions were never just about scale. Each one seeded a capability that would matter later. Taro gave Sun dermatology. DUSA gave them a US field force. Ranbaxy gave them a manufacturing footprint in forty countries. By the time the integration dust settled, Sun had the infrastructure to attempt something far more ambitious than generics.
The generic drug business has a structural problem: it rewards you for making things cheaper, not better. By 2015, Sun was the fifth-largest generic company on the planet and facing the same margin compression as every other manufacturer in the space. The question was whether the company that had spent three decades perfecting the economics of imitation could learn the economics of invention.
The answer came through dermatology, ophthalmology, and oncology. In 2014, Sun had licensed tildrakizumab, a monoclonal antibody, from Merck — a quiet deal that attracted almost no attention. It launched as Ilumya in the United States in 2018 for moderate-to-severe plaque psoriasis. Winlevi followed for acne in 2020 — the first new mechanism of action in acne treatment in nearly four decades. Cequa for dry eye disease. Odomzo for basal cell carcinoma.
The numbers tell the story of the pivot. In FY18, innovative medicines accounted for 7.3% of Sun’s sales. By FY25, they were 20% — and growing at a 23% compound annual rate. Ilumya alone generated $681 million in FY25. In 2023, Sun acquired Concert Pharmaceuticals for deuruxolitinib, a JAK inhibitor for alopecia areata, which launched as Leqselvi. In early 2025, it acquired Checkpoint Therapeutics for cosibelimab, an immuno-oncology antibody. The company that once sold only what others had invented now runs its own clinical trials and maintains five new active substances in its development pipeline.
Two-thirds of Sun’s revenue comes from outside India. In the United States, it is among the largest generic manufacturers and holds a leading position in dermatology prescriptions per IQVIA. In India, it holds 8.4% market share per AIOCD AWACS and ranks first by prescriptions across specialist categories including psychiatry, cardiology, dermatology, and urology. In emerging markets, it operates across eighty countries with manufacturing in Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria, Morocco, and Russia. Market capitalisation stood at US$45 billion as of February 2026.
Sun operates forty manufacturing sites across India, the Americas, Asia, Africa, Australia, and Europe, including fourteen dedicated API facilities. Of these, fifteen carry US FDA registration: twelve formulation plants in India and three in the United States. This is not a company that outsources production and puts its label on the box — it controls the supply chain from molecule synthesis to finished dosage, a vertical integration that gives it both cost advantage and quality accountability.
Sun’s plants operate under continuous US-FDA oversight; like every global manufacturer, it has received and remediated inspection findings. The regulatory discipline required to maintain 734 approved US FDA drug applications (680 ANDAs, 53 NDAs, 1 BLA) and 347 Indian Patent Office grants is itself a form of institutional knowledge that cannot be quickly replicated.
A pharmaceutical company that sells medicines to a hundred countries but ignores the villages around its own factories would be a contradiction. Sun Pharma’s CSR operation, which spent INR 1,424 million in FY 2024–25, is built on the premise that the same logistics and medical expertise that move drugs across borders can move healthcare into communities that have neither a clinic nor a paved road.
In FY 2024–25, Sun’s programmes reached 4.47 million people across sixteen Indian states through healthcare, education, water, and environmental initiatives. Of these, 240,254 were served directly by thirteen Mobile Healthcare Units — fully equipped clinics on wheels operating in 217 villages and delivering primary care, maternal health services, and disease screenings. Thirty-five Primary Health Centres were upgraded, and 127,012 people gained access to safe drinking water through 38 community water installations.
In cancer care, Sun launched SUNKalp, a community-based screening programme in Mumbai, and trained 50,000 first responders in CPR across thirty cities through its “Making India Heart Strong” initiative. The school eye health programme screened 17,095 students and provided 1,829 with corrective glasses. The “Live Well with Diabetes” project distributed practical management kits to 110,000 patients.
Education absorbs two-thirds of the CSR budget. The SUnVidya programme upgraded 143 schools serving 56,312 students. “Chalk to Click” installed 888 smart classrooms across Uttarakhand, Chhattisgarh, and Maharashtra, reaching 1.86 million children; an independent assessment found learning outcomes in English and mathematics improved by 30–51%. Nineteen new Anganwadi centres were constructed and twenty-eight renovated, providing early childhood care to 8,687 children.
The company’s climate work planted more than two million saplings across seven states, created water storage capacity of 10.38 million kilolitres benefiting 97,871 people, and distributed 2,715 improved cookstoves that offset an estimated 12,217 metric tonnes of CO₂ annually. At Wadala in Mumbai, the Shantilal Shanghvi Cancer Sanatorium — a 100-bed, 19-floor facility — is under construction alongside a 50-bed eye institute.
Sources: Sun Pharma Annual Reports FY2014–15 through FY2024–25. Sun Pharma Investor Presentation, February 2026. Sun Pharma CSR Annual Report 2024–25. US FDA facility registration data. IQVIA (US market rankings). AIOCD AWACS (India market share and specialist rankings).